These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
450 related articles for article (PubMed ID: 16879967)
21. Validation of two clinically useful assays for evaluation of JAK2 V617F mutation in chronic myeloproliferative disorders. McClure R; Mai M; Lasho T Leukemia; 2006 Jan; 20(1):168-71. PubMed ID: 16270039 [No Abstract] [Full Text] [Related]
22. JAKing up hematopoietic proliferation. Shannon K; Van Etten RA Cancer Cell; 2005 Apr; 7(4):291-3. PubMed ID: 15837617 [TBL] [Abstract][Full Text] [Related]
23. LKB1 is a master kinase that activates 13 kinases of the AMPK subfamily, including MARK/PAR-1. Lizcano JM; Göransson O; Toth R; Deak M; Morrice NA; Boudeau J; Hawley SA; Udd L; Mäkelä TP; Hardie DG; Alessi DR EMBO J; 2004 Feb; 23(4):833-43. PubMed ID: 14976552 [TBL] [Abstract][Full Text] [Related]
25. Complexes between the LKB1 tumor suppressor, STRAD alpha/beta and MO25 alpha/beta are upstream kinases in the AMP-activated protein kinase cascade. Hawley SA; Boudeau J; Reid JL; Mustard KJ; Udd L; Mäkelä TP; Alessi DR; Hardie DG J Biol; 2003; 2(4):28. PubMed ID: 14511394 [TBL] [Abstract][Full Text] [Related]
26. Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes. Lasho TL; Mesa R; Gilliland DG; Tefferi A Br J Haematol; 2005 Sep; 130(5):797-9. PubMed ID: 16115143 [No Abstract] [Full Text] [Related]
27. Identification of an acquired mutation in Jak2 provides molecular insights into the pathogenesis of myeloproliferative disorders. Pesu M; O'Shea J; Hennighausen L; Silvennoinen O Mol Interv; 2005 Aug; 5(4):211-5. PubMed ID: 16123535 [No Abstract] [Full Text] [Related]
28. Methods to assess small molecule allosteric modulators of the STRAD pseudokinase. Qing T; Liu J; Liu F; Mitchell DC; Beresis RT; Gordan JD Methods Enzymol; 2022; 667():427-453. PubMed ID: 35525550 [TBL] [Abstract][Full Text] [Related]
29. Hemizygous/homozygous and heterozygous JAK2 mutation detected in plasma of patients with myeloproliferative diseases: correlation with clinical behaviour. Ma W; Kantarjian H; Verstovsek S; Jilani I; Gorre M; Giles F; Cortes J; O'Brien S; Keating M; Albitar M Br J Haematol; 2006 Aug; 134(3):341-3. PubMed ID: 16787500 [No Abstract] [Full Text] [Related]
30. CSF-1 signal transduction. Hamilton JA J Leukoc Biol; 1997 Aug; 62(2):145-55. PubMed ID: 9261328 [TBL] [Abstract][Full Text] [Related]
31. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway. Nguyen MH; Ho JM; Beattie BK; Barber DL J Biol Chem; 2001 Aug; 276(35):32704-13. PubMed ID: 11435425 [TBL] [Abstract][Full Text] [Related]